Skip to main content

Mallinckrodt to sell BioVectra to HIG

16th September 2019

Submitted by:

Andrew Warmington

UK-based biopharmaceuticals producer Mallinckrodt has agreed to sell is CDMO subsidiary BioVectra to HIG Capital, a private equity firm. The price includes a an upfront payment of $135 million, a long-term note for $40 million and contingent payments of up to $75 million, depending on the BioVectra’s future growth. The deal is expected to close in Q4.

BioVectra has two sites in Canada at Charlottetown, Prince Edward Island, and Windsor, Nova Scotia. These offer a mixture of GMP microbial fermentation, complex chemistry for high potency APIs, biologics and drug development to the biopharma sector. It will continue to supply a specific API, thought to be for H.P. Achtar Gel, to Mallinckrodt’s Specialty Brands business under a long-term arrangement.

Mallinkrodt had acquired BioVectra in 2014, as part of its $5.6 billion acquisition of Questcor, which made Achtar. This is widely used to treat inflammatory and autoimmune disorders. Only five months before, in March, it announced plans to invest $107 million to expand the two plants, doubling the workforce to around 300. The Canadian gave it $28 million in support.

CEO and president Mark Trudeau commented that the sale “continues to advance Mallinckrodt's strategic focus on branded, high-growth biopharmaceuticals by monetising a non-core business”. However, some observers believe that the sale was prompted in part by recent events connected to Achtar. 

In 2018, Mallinckrodt became embroiled in several scandals, first coming under criticism and harsh media coverage for raising the already very high price of the drug to $38,000/vial since acquiring Questcor. It also came under investigation from the US Drug Enforcement Agency (DEA) for alleged failure to stop drug pushers getting hold of its oxycodone opioid.

Finally, a former marketing executive started legal action against the firm, claiming that it had used ‘dirty data’ to persuade health insurance companies to cover Acthar. Mallinckrodt had already paid $100 million to the Federal Trade Commission to settle claims that it had bought out a potential competitor in 2013. Another suit is ongoing about unfair competition from Medicare Advantage.

Last December, the firm announced plans to spin off its APIs and speciality generics operations, including BioVectra, plus the constipation drug Amitiza, from the speciality brands. This was supposed to take place in 2H 2019. Much was thought to depend on the success of Achtar in ongoing trials, including for one entirely new indication. This is by far the company’s biggest-selling drug, generating $1.2 billion/year in sales.

Shortly before the sale of BioVectra was announced, Mallinckrodt and two subsidiaries reached an agreement with two counties in Ohio to settle to multi-district opioid litigation. Under this, it will pay $24 million in cash and donate $6 million in generic products, including addiction treatment products, and all named Mallinckrodt entities will be dismissed with prejudice from the lawsuit. However, other such claims continue.

Three days earlier, the company had finalised an agreement with the US Department of Justice to pay $15.4 million to resolve a civil False Claims Act dating back to 2012 related to an investigation into Questcor’s legacy sales and marketing activities, without any admission of wrongdoing. Mallinckrodt also had the disappointment in August when the US Court of Appeals for the Federal Circuit upholding a Federal District Court’s decision rejecting a claim that Praxair’s nitric oxide drug product delivery system infringed its own patent for the INOmax Total Care delivery system.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington